Clinical trial
Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) on Ethanol in Heavy Drinkers With PTSD - Alcohol Interaction Study
NCT04827056 is registered in ClinicalTrials.gov with Pharmacotherapies for Alcohol and Substance Use Disorders Alliance as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) on Ethanol in Heavy Drinkers With PTSD - Alcohol Interaction Study
- Lead sponsor
- Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 9, 2021
- Completion date
- June 2, 2023
- Enrollment
- 10 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
alcohol use disorder (aud), post traumatic stress disorder (ptsd)